Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Myeloid, Acute

Explore clinical trials studying Leukemia, Myeloid, Acute. Study availability and eligibility vary by location and protocol.

2,459 public trials 541 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Myeloid, Acute trial results

Recruiting

VABu Conditioning in Elderly AML HSCT

NCT07583888

Conditions
Acute Myeloid Leukemia (AML), Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Hematologic Diseases, +6 more
Locations
  • The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China
View Trial Details
Recruiting

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

NCT07044687

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Fortis Memorial Research Institute /ID# 268697 Gurgaon, Haryana, India
  • Mazumdar Shaw Medical Center /ID# 270677 Bengaluru, Karnataka, India
  • Regional Cancer Centre /ID# 268785 Thiruvananthapuram, Kerala, India
  • LMMF's Deenanath Mangeshkar Hospital & Research Center /ID# 268781 Pune, Maharashtra, India
View Trial Details
Recruiting

Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

NCT07243483

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Centre Hospitalier Pierre Oudot Bourgoin, France
  • CHU de Grenoble Grenoble, France
  • Centre Leon Berard Lyon, France
  • CHU de Saint-Étienne Saint-Etienne, France
View Trial Details
Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

NCT05907057

Conditions
Acute Myeloid Leukemia (AML), Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • AKH - Medizinische Universität Wien Vienna, Austria
  • Klinikum Wels-Grieskirchen GmbH Wels, Austria
  • Institut Paoli Calmettes Marseille, Bouches-du-Rhône, France
  • CHU CAEN - Hôpital de la Côte de Nacre Caen, Calvados, France
View all 15 locations
View Trial Details
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592

Conditions
B-cell Malignancy, Low-grade, Blood Protein Disorders, Bone Marrow Diseases, +36 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana Farber Cancer Institute at St. Elizabeth's Brighton, Massachusetts, United States
  • Dana Farber Cancer Institute at Merrimack Valley Methuen, Massachusetts, United States
  • Dana Farber Cancer Institute at Milford Regional Medical Center Milford, Massachusetts, United States
View Trial Details
Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT04771572

Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +48 more
Locations
  • University of Chicago Chicago, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • University of North Carolina Chapel Hill, North Carolina, United States
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View Trial Details

Related conditions